Inactive Instrument

Highlights Eidos Therapeutics, Inc.

Equities

EIDX

US28249H1041

Highlights

Unlock all the news: Be the first to know and act before the market!

BridgeBio Pharma, Inc. completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc..	21-01-25	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-29	CI
BridgeBio Pharma, Inc. entered into a definitive agreement to acquire remaining 36.3% stake in Eidos Therapeutics, Inc. for $1 billion.	20-10-04	CI
Eidos Therapeutics, Inc. Expects Enrollment of Patients in Its Phase 3 Clinical Trial of Acoramidis in ATTR-CM Patients	20-08-06	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-06	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-08	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-02-26	CI
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Present Data from Phase 2 Open Label Extension Suggesting Long-Term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures	19-11-16	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-31	CI
BridgeBio Pharma, Inc. cancelled the acquisition of 33.4% stake in Eidos Therapeutics, Inc..	19-10-13	CI
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation	19-09-30	CI
Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis Investigational Medicine	19-09-09	CI
BridgeBio Pharma, Inc. made a non-binding proposal to acquire 33.4% stake in Eidos Therapeutics, Inc. for approximately $470 million.	19-08-07	CI
Eidos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-01	CI
Eidos Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Eidos Therapeutics, Inc. Completes Phase 1 and Phase 2 Studies of AG10	19-04-15	CI
Eidos Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018	19-04-15	CI
Eidos Therapeutics, Inc. Announces Initiation and Design of its Pivotal Global Phase 3 Trial (ATTRibute-CM) of AG10 in Patients with Transthyretin Amyloid Cardiomyopathy	19-02-27	CI
Eidos Therapeutics, Inc. Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy	18-11-10	CI
Eidos Therapeutics, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eidos Therapeutics, Inc.

Equities

EIDX

US28249H1041

Highlights

Filters